Centre Léon Berard Lyon

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)	Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence	Active, not recruiting	Phase 2	2026-04-02		NCT03703050

Clinical trials